Table 4.
Cox Regression Model Results for Flow Markers When Adjusting for Age, Having 2 or More Comorbidities, and Prior Radiation Therapy Exposurea
| Adjusting for All Covariates | Adjusting Just for Comorbidities | ||||
|---|---|---|---|---|---|
| Flow Marker | No. With Abnormal Expression | HR (95% CI) | P Value | HR (95% CI) | P Value |
| CD13/HLA-DR | 21 | 2.97 (1.37-6.46) | .006 | 2.68 (1.29-5.61) | .009 |
| CD7 | 4 | 4.60 (1.19-17.77) | .027 | 4.70 (1.35-16.39) | .015 |
| CD2 | 3 | 0.72 (0.10-5.43) | .75 | 0.65 (0.09-4.80) | .67 |
| CD13/CD16 | 6 | 1.11 (0.25-4.85) | .89 | 1.03 (0.24-4.36) | .97 |
| CD45 | 24 | 0.94 (0.42-2.10) | .88 | 0.87 (0.40-1.92) | .73 |
| CD56 | 4 | 0.36 (0.05-2.75) | .32 | 0.32 (0.04-2.40) | .27 |
| SSC | 7 | 0.90 (0.26-3.14) | .87 | 1.06 (0.32-3.52) | .93 |
| CD13/HLA-DR, CD13/CD16, or CD7 (vs not any) | 26 | 2.56 (1.20-5.46) | .015 | 2.37 (1.14-4.93) | .021 |
CI, confidence interval; HR, hazard ratio; MN, myeloid neoplasia.
aEach row in this table reflects a separate multivariable Cox regression model, where the results associated with the marker are presented for risk of MN or death when adjusting for all covariates of interest as well as for having ≥2 comorbidities, which was the most influential of the 3 on risk of MN. CD13/CD16, CD2, CD7, CD56, and SSC should be interpreted with caution because of the small number of patients (<10) with abnormal expression of those single markers.